Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
Bingshe Han
, Dongkyoo Park
, Rui Li
, Maohua Xie
, Taofeek K. Owonikoko
, Guojing Zhang
, Gabriel L. Sica
, Chunyong Ding
,
Jia Zhou
, Andrew T. Magis
, Zhuo G. Chen
, Dong M. Shin
, Suresh S. Ramalingam
, Fadlo R. Khuri
, Walter J. Curran
, Xingming Deng
Pharmacology & Toxicology
Research output
:
Contribution to journal
›
Article
›
peer-review
107
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Small Molecules
100%
B-cell Lymphoma 2 (Bcl-2)
100%
Lung Cancer Treatment
100%
Anti-apoptotic
28%
Lung Cancer
28%
BH4 Domain
28%
Inducer
14%
Clinical Trials
14%
Cell Death
14%
Conformational Change
14%
High Affinity
14%
MTOR Inhibitor
14%
Tumor Tissue
14%
Cancer Tumor
14%
Effective Dose
14%
Lung Cancer Cells
14%
Cancer Xenograft
14%
RAD001
14%
Anticancer Target
14%
High Selectivity
14%
Normal Tissue Toxicity
14%
Lung Cancer Outcomes
14%
Biochemistry, Genetics and Molecular Biology
Small Molecule
100%
Cancer Cell
50%
Cell Death
50%
Conformational Change
50%
Clinical Trial
50%
Anticancer
50%
Mammalian Target of Rapamycin
50%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Antiapoptotic
40%
Clinical Trial
20%
Neoplasm
20%
Everolimus
20%